Subject Area: Hematology Title: USE OF LOW-DOSE DECITABINE WITH OR WITHOUT TYROSINE KINASE INHIBITORS IN ADVANCED PHASE CHRONIC MYELOGENOUS LEUKEMIA: A SYSTEMIC REVIEW AND METAANALYSIS Author List: Maureen Via M. Comia, MD, FPCP, Charles Eryll S. Sy, MD, FPCP, Jomell C. Julian, MD, FPCP, FPCHTM1 1Section of Clinical Hematology, University of Santo Tomas Hospital, España, Manila Philippines 1008 ABSTRACT Rationale: Progression of Chronic Myelogenous Leukemia (CML) to more advanced phases can involve hypermethylation, which is correlated to resistance or intolerance to imatinib. This hypermethylation has also been found to be a negative prognostic factor independent of imatinib response and from CML phase, thus decitabine, a hypomethylating agent, can be an attractive treatment option for advanced phase CML. Objective: This systemic review and meta-analysis aims to investigate the role of low-dose decitabine among patients with advanced phase CML. Methodology: This was performed according to the statement of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Results: Four (4) studies from 86 articles screened were eligible to be assessed in this systemic review and meta-analysis. These were phase I/II trials involving 81 advanced phase CML patients and used low-dose decitabine (5 to 20 mg/m2), with two studies using tyrosine kinase inhibitors. Outcomes of hematologic and cytogenetic response, and survival were assessed in the meta-analysis; with hematologic response being favored among advanced phase CML patients upon exposure with low-dose decitabine (p=0.05). Survival was also favored among responders to low-dose decitabine, however this was not significant. Discussion and Conclusion: Low-dose decitabine can be an effective and safe treatment option in advanced phase CML, especially in more frail patients that could not tolerate more intensive chemotherapy regimens. However, this study is limited by few studies available on this topic, thus further randomized controlled trials can be investigated to define the role of decitabine and its optimal dose among this subset of patients. Keywords: Chronic myelogenous leukemia, Decitabine, Advanced phase Conflict of Interest: The authors have no conflict of interest to declare regarding the publication of this article. Funding Source: None Corresponding Author: Maureen Via M. Comia, MD, FPCP maucomia@gmail.com +639178396329

The authors have declared no competing interest.

N/A

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

N/A

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors and contained in the manuscript.